Elevated levels of D-dimers increase the risk of ischaemic and haemorrhagic stroke: Findings from the EPICOR Study

Thrombosis and Haemostasis

Volumn 112, Issue 5, 2014, Pages 941-946

  Di Castelnuovo, Augusto ^a   Agnoli, Claudia ^b   de Curtis, Amalia ^a   Giurdanella, Maria Concetta ^c   Sieri, Sabina ^b   Mattiello, Amalia ^d   Matullo, Giuseppe ^e,f   Panico, Salvatore ^d   Sacerdote, Carlotta ^f,g   Tumino, Rosario ^c   Vineis, Paolo ^g,h   de Gaetano, Giovanni ^a   Donati, Maria Benedetta ^a   Iacoviello, Licia ^a  

^a IRCCS NEUROMED   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Cancer Registry ASP Ragusa   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f Human Genetics Foundation   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cerebrovascular disease; Coagulation factors; Epidemiological studies; Risk factors; Stroke prevention

Indexed keywords

C REACTIVE PROTEIN; D DIMER; GLUCOSE; TRIACYLGLYCEROL; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; ARTICLE; BLOOD SAMPLING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; TURBIDIMETRY; AGED; BLOOD; CASE CONTROL STUDY; CEREBRAL HEMORRHAGE; CLINICAL TRIAL; COMORBIDITY; HYPERTENSION; INFLAMMATION; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CEREBRAL HEMORRHAGE; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 84908547988     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-04-0297     Document Type: Article

References (42)

1. Feigin VL, et al. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2: 43-53.
2. van Holten TC, et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One 2013; 22: e62080.
3. Meade TW, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet1986; ii: 533-537.
4. Gorog DA. Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol 2010; 55: 2701-2709.
5. Cushman M, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 2003; 101: 1243-1248.
6. Huisman MV, Klok FA. How I diagnose acute pulmonary embolism. Blood 2013; 121: 4443-4448.
7. Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Haemost 2012; 38: 673-682.
8. Danesh J, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103: 2323-2327.
9. Lowe GDO, Rumley A. Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events. Thromb Haemost 1999; 82: 667-672.
10. Fowkes FGR, et al. Cross-linked fibrin degradation products, risk of coronary heart disease, and progression of peripheral arterial disease. Lancet 1993; 342: 84-86.
11. Ridker PM, et al. Plasma concentration of cross-linked fibrin degradation products (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-2240.
12. Moss AJ, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99: 2517-2522.
13. Cortellaro M, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischaemic events in atherosclerotic patients. A case-control study. The PLAT Group. Arterioscler Thromb 1993; 13: 1412-1417.
14. Cushman M, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19: 493-498.
15. Lowe GD, et al. C-reactive protein, fibrin D-dimer, and incident ischaemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001; 21: 603-610.
16. Lowe GDO, et al. Fibrin D-dimer, tissue plasminogen activator, tissue plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998; 79: 129-133.
17. Di Castelnuovo A, et al. Association of D-dimer levels with all-cause mortality in a healthy adult population: findings from the MOLI-SANI study. Haematologica 2013; 98: 1476-1480.
18. Folsom AR, et al. Multiethnic Study of Atherosclerosis Investigators. Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality. Am J Hematol 2009; 84: 349-353.
19. Ay C, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012; 97: 1158-1164.
20. Donati MB. Thrombosis and cancer: a personal view. Thromb Haemost 2007; 98: 126-128.
21. Hasan N, et al. Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review. Br J Clin Pharmacol 2012; 74: 230-240.
22. Smith FB, et al. Haemostatic factors as predictors of ischaemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-3325.
23. Smith FB, et al. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998; 100: 758-763.
24. Smith A, et al. Which haemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischaemic stroke? The Caerphilly Study. Circulation 2005; 112: 3080-3087.
25. Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997; 26 (Suppl 1): S6-14.
26. Palli D, et al. A molecular epidemiology project on diet and cancer: the EPICItaly Prospective Study. Design and baseline characteristics of participants. Tumori 2003; 89: 586-593.
27. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
28. Pala V, et al. Diet in the Italian EPIC cohorts: presentation of data and methodological issues. Tumori 2003; 89: 594-607.
29. Le Polain de Waroux O, et al. The case-cohort design in outbreak investigations. Euro Surveill 2012; 17: 1-5.
30. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986; 73: 1-11.
31. Wareham NJ, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2003; 6: 407-413.
32. Matijevic N, Wu KK. Hypercoagulable states and strokes. Curr Atheroscler Rep 2006; 8: 324-329.
33. Stott DJ, et al. Haemostasis in ischaemic stroke and vascular dementia. Blood Coagul Fibrinol 2001; 12: 651-657.
34. Whiteley W, et al. Blood biomarkers for the diagnosis of acute cerebrovascular diseases: a prospective cohort study. Cerebrovasc Dis 2011; 32: 141-147.
35. Carcaillon L, et al. Elevated plasma fibrin D-dimer as a risk factor for vascular dementia: the Three-City cohort Study. J Thromb Haemost 2009; 1972-1978.
36. Wannamethee SG, et al. Fibrin D-dimer, tissue-type plasminogen activator, von Willebrand factor, and risk of incident stroke in older men. Stroke 2012; 43: 1206-1211.
37. Fujii Y, et al. Haemostatic activation in spontaneous intracerebral haemorrhage. Stroke 2001; 32: 883-890.
38. Delgado P, et al. Plasma d-dimer predicts poor outcome after acute intracerebral haemorrhage. Neurology 2006; 67: 94-98.
39. Varoglu AO, et al. Prognostic values of lesion volume and biochemical markers in ischaemic and haemorrhagic stroke: a stereological and clinical study. Int J Neurosci 2009; 119: 2206-2218.
40. Ariëns RA, et al. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 2002; 359: 667-671.
41. Lip GY, et al. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation. Int J Cardiol 1995; 51: 245-251.
42. Lip GY, et al. Fibrin D-dimer and b-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: effects of introducing ultralow-dose warfarin and aspirin. Circulation 1996; 94: 425-431.